Defiance Nasdaq Junior Biotechnology ETF
IBBJ
IBBJ was delisted on the 2nd of December, 2021.
8 hedge funds and large institutions have $418K invested in Defiance Nasdaq Junior Biotechnology ETF in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
11% less funds holding
Funds holding: 9 → 8 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
45% less capital invested
Capital invested by funds: $761K → $418K (-$343K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
+$47.9K |
| 2 |
TWM
Tradition Wealth Management
Edina,
Minnesota
|
+$22.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$274K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$57.7K |
| 3 |
RWB
RMR Wealth Builders
Montclair,
New Jersey
|
-$50K |
| 4 |
MF
Manchester Financial
Westlake Village,
California
|
-$14K |
| 5 |
EIP
Ellis Investment Partners
Berwyn,
Pennsylvania
|
-$6.73K |
IBBJ Hedge Fund Activity: Q2 2021 in Review
8 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Defiance Nasdaq Junior Biotechnology ETF (IBBJ) for Q2 2021, worth a combined $418K — down 45% from $761K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IBBJ and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Aptus Capital Advisors, opening a new position worth an estimated $47.9K. The largest seller was CIBC World Market, exiting entirely with an estimated $274K sold.
- 8 institutional investors held Defiance Nasdaq Junior Biotechnology ETF (IBBJ) as of Q2 2021, down from 9 in Q1 2021.
- Funds reported $418K of Defiance Nasdaq Junior Biotechnology ETF stock for Q2 2021, down 45% quarter-over-quarter.
- 2 funds opened new Defiance Nasdaq Junior Biotechnology ETF positions in Q2 2021 and 3 closed out, a net change of -1 holder.
- The largest Defiance Nasdaq Junior Biotechnology ETF buyer in Q2 2021 was Aptus Capital Advisors, an estimated $47.9K added.
- The largest Defiance Nasdaq Junior Biotechnology ETF seller in Q2 2021 was CIBC World Market, an estimated $274K sold.
Based on aggregated 13F filings for Q2 2021.